Stephens & Co. Upgrades NeoGenomics to Overweight, Raises Price Target to $18
Portfolio Pulse from richadhand@benzinga.com
Stephens & Co. analyst Jacob Johnson has upgraded NeoGenomics (NASDAQ:NEO) from Equal-Weight to Overweight and raised the price target from $16 to $18.
August 21, 2023 | 3:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NeoGenomics has been upgraded to Overweight from Equal-Weight by Stephens & Co. The price target has also been raised from $16 to $18.
The upgrade from Equal-Weight to Overweight by Stephens & Co. indicates a positive outlook for NeoGenomics. The raised price target from $16 to $18 suggests that the analyst believes the stock has potential for further growth. This could lead to increased investor interest and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100